
Rapihaler: Asthma: Symbicort Rapihaler is indicated in the treatment of asthma to achieve overall asthma control, including the prevention and relief of symptoms as well as the reduction of the risk of exacerbations.
Symbicort Rapihaler is indicated for treatment of asthma, where the use of inhaled corticosteroids is appropriate.
Chronic Obstructive Pulmonary Disease (COPD): Symbicort Rapihaler is indicated in the regular treatment of patients with severe COPD (FEV1 <50% predicted normal), with frequent symptoms and a history of exacerbations despite regular bronchodilator therapy.